Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CUMB | ISIN: IT0005452658 | Ticker-Symbol: 87N
Frankfurt
12.08.25 | 21:55
18,500 Euro
-2,12 % -0,400
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
STEVANATO GROUP SPA Chart 1 Jahr
5-Tage-Chart
STEVANATO GROUP SPA 5-Tage-Chart
RealtimeGeldBriefZeit
18,50018,90012.08.
18,40018,90012.08.

Aktuelle News zur STEVANATO GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
DiStevanato Group S.p.A. - 6-K, Report of foreign issuer2
STEVANATO GROUP Aktie jetzt für 0€ handeln
05.08.Stevanato Group S.p.A. - 6-K, Report of foreign issuer1
05.08.Stevanato Group S.p.A.: Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025352Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery...
► Artikel lesen
23.07.Stevanato Group Secures $235.4 Million in Financing1
23.07.Stevanato secures €200 million financing for global expansion1
23.07.Stevanato secures €200M in financing1
23.07.Stevanato Group S.p.A.: Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.523Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced...
► Artikel lesen
22.07.Stevanato Group S.p.A.: Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025296Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced...
► Artikel lesen
05.06.Stevanato Group auf Jefferies-Konferenz: Strategisches Wachstum und Expansion1
13.05.Stevanato Group S.p.A. - 6-K, Report of foreign issuer2
09.05.Stevanato Group S.p.A.: Stevanato Group to Participate in Upcoming Investor Conferences271Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today...
► Artikel lesen
08.05.Stevanato Group Non-GAAP EPS of €0.10 in-line, revenue of €256.6M misses by €23.36M5
08.05.Stevanato Group S.p.A.: Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025330Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today...
► Artikel lesen
05.05.Stevanato Group declares $0.0613 dividend3
02.05.Stevanato Group S.p.A. - 6-K, Report of foreign issuer1
24.04.Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025333Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced...
► Artikel lesen
14.03.Stevanato Group S.p.A. - 6-K, Report of foreign issuer1
11.03.Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum277Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced...
► Artikel lesen
07.03.Stevanato Group reports Q4 results1
06.03.Stevanato Group S.p.A. - 20-F, Annual and transition report of foreign private issuers-
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1